LB Pharmaceuticals has started its pivotal Phase III NOVA-2 trial to assess the safety and efficacy of its investigational ...
Wave Life Sciences will advance the drug to the Phase IIa portion of the trial. Credit: Piotr Swat / Shutterstock.com Wave Life Sciences’ stock has crashed by nearly 50% after its Phase I obesity ...
AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...
The primary endpoint measures percent change in body weight from baseline after 78 weeks compared to placebo. Credit: Mateus Matumona Bazola / Shutterstock.com. Viking Therapeutics has completed ...
Mariano Ponz-Sarvise, Eduardo Castañón, and Irene de Dios from CUN; Michel van Harten, Patricia Aymerich, Danny den Hamer, and Mar Soto Ruiz de la Torre from myTomorrows. Credit: myTomorrows / PR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results